Coherus Oncology
CHRS
117 hedge funds and large institutions have $938M invested in Coherus Oncology in 2019 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 17 closing their positions.
230% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $358K
58% more capital invested
Capital invested by funds: $595M → $938M (+$343M)
35% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 31
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
5% more funds holding
Funds holding: 111 → 117 (+6)
2.69% more ownership
Funds ownership: 96.6% → 99.29% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$13.5M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.2M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$12.1M |
| 5 |
Millennium Management
New York
|
+$9.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$18.4M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
-$16.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.04M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.57M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.46M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JG
126
Jefferies Group
New York
| – | -$91K | -10,060 | Closed |
|
|
RBFC
127
Roman Butler Fullerton & Co
St Louis,
Missouri
| – | -$122K | -10,000 | Closed |
|
128
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$12K | -1,348 | Closed |
|
|
QT
129
Quantamental Technologies
White Plains,
New York
| – | -$12K | -1,286 | Closed |
|
|
AIM
130
Assured Investment Management
New York
| – | -$11K | -1,219 | Closed |
|
131
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$7K | -737 | Closed |
|
132
Group One Trading
Chicago,
Illinois
| – | -$1.87K | -140 | Closed |
|
CHRS Hedge Fund Activity: Q1 2019 in Review
117 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2019, worth a combined $938M — up 58% from $595M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CHRS positions and 17 closed out — a net gain of 6 holders — while 42 added to existing stakes and 31 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $13.5M. The largest seller was Deutsche Bank, cutting an estimated $18.4M.
- 117 institutional investors held Coherus Oncology (CHRS) as of Q1 2019, up from 111 in Q4 2018.
- Funds reported $938M of Coherus Oncology stock for Q1 2019, up 58% quarter-over-quarter.
- 23 funds opened new Coherus Oncology positions in Q1 2019 and 17 closed out, a net change of +6 holders.
- The largest Coherus Oncology buyer in Q1 2019 was JP Morgan Chase, an estimated $13.5M added.
- The largest Coherus Oncology seller in Q1 2019 was Deutsche Bank, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2019.